Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 416858 in ESRD patients on hemodialysis
NCT02553889Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Nov 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of fesomersen in end stage renal disease (ESRD), sponsored by Ionis Pharmaceuticals. Started Oct 2015; status: completed.
02
Drugs
fesomersen
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT02553889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553889.